Samuel Bates Martin sold $608k of CLDX
SVP AND CFO at Celldex Therapeutics, Inc.. 17,172 shares at an average of $35.42, traded Jun 14, 2024, filed Jun 18, 2024.
Score components
- +22RoleCFO
- +20Trade size$608k at market
- +10Share of holdings soldSold 38% of holdings
- +15Cluster6 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-24-017363, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 14, 2024 | MOption exercise Common Stock | +3,201 | $9.02 | $29k | 28,329 | Jun 18, 2024 |
| Jun 14, 2024 | MOption exercise Common Stock | +16,968 | $10.38 | $176k | 45,297 | Jun 18, 2024 |
| Jun 14, 2024 | SOpen-market sale Common Stock | -17,172 | $35.42 | $608k | 28,125 | Jun 18, 2024 |
| Jun 14, 2024 | MOption exercise Incentive Stock Option (Right to Buy)derivative | -3,201 | $0.00 | $0 | 0 | Jun 18, 2024 |
| Jun 14, 2024 | MOption exercise Incentive Stock Option (Right to Buy)derivative | -16,968 | $0.00 | $0 | 63,632 | Jun 18, 2024 |
Related signals
Other insiders at Celldex Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | CLDXsell Celldex Therapeutics, Inc. | Freddy A. Jimenez SVP & GENERAL COUNSEL | $121k 4,166 shares | -12% | |
| 38Weak | CLDXsell Celldex Therapeutics, Inc. | Richard M. Wright SR. VP & CCO | $1.2M 49,298 shares | -70% | |
| 15Weak | CLDXsell Celldex Therapeutics, Inc. | Freddy A. Jimenez SVP & GENERAL COUNSEL | $19k 771 shares | -2% | |
| 45Moderate | CLDXbuy Celldex Therapeutics, Inc. | Anthony S Marucci PRESIDENT & CEO | $308k 11,500 shares | +40% | |
| 60Notable | Celldex Therapeutics, Inc. | Elizabeth Crowley SR. VP & CPDO | $1.0M 30,000 shares | -77% | |
| 75Notable | Celldex Therapeutics, Inc. | Diane C. Young SVP, CHIEF MEDICAL OFFICER | $1.6M 45,000 shares | -96% | |
| 53Moderate | Celldex Therapeutics, Inc. | Elizabeth Crowley SR. VP & CPDO | $526k 15,000 shares | -62% | |
| 33Weak | Celldex Therapeutics, Inc. | Freddy A. Jimenez SVP & GENERAL COUNSEL | $269k 8,006 shares | -24% | |
| 60Notable | Celldex Therapeutics, Inc. | Richard M. Wright SR. VP & CCO | $1.6M 46,844 shares | -69% | |
| 60Notable | Celldex Therapeutics, Inc. | Margo Heath-Chiozzi SVP OF REGULATORY AFFAIRS | $2.0M 58,369 shares | -81% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.